Evidence map›Paper›PMID 42423920›Full record

ReviewMolecular diversity2026

Multicomponent reactions for protein tyrosine phosphatase inhibitors.

Eyad A H Mohammed, Taoda Shi, Wenhao Hu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Eyad A H MohammedGuangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China.
Taoda ShiGuangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China. shitd@mail.sysu.edu.cn.ORCID http://orcid.org/0000-0002-4250-3779
Wenhao HuGuangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China. huwh9@mail.sysu.edu.cn.ORCID http://orcid.org/0000-0003-1511-2614

Funding

National Key R&D Program of China Foundation (Grant No. 2025GXNSFDA04240008).
6 · The paper itself

Abstract

Protein tyrosine phosphatases (PTPs) are pivotal regulators of cellular signaling and potential therapeutic targets for cancer, metabolic disorders, and autoimmune diseases. However, the development of PTP inhibitors remains challenging due to the highly conserved catalytic pocket, the poor membrane permeability of phosphotyrosine mimetics, and difficulties in achieving subtype selectivity. Multicomponent reactions (MCRs) offer a powerful solution by enabling the rapid and modular synthesis of structurally diverse, medicinally relevant scaffolds in a one-pot manner. Through the flexible combination of building blocks, MCRs facilitate efficient optimization of polarity, topology, conformational rigidity, and secondary-pocket engagement, thereby accelerating the discovery of selective and drug-like PTP inhibitors. This review provides the first systematic overview of MCR-enabled PTP inhibitor discovery. The discussion is organized according to major MCR strategies and PTP target classes, highlighting how MCR chemistry has been applied to rapidly construct focused libraries, identify novel scaffolds, and optimize potency and selectivity. Key design concepts-including phosphotyrosine mimicry, fragment extension, conformational constraint, and stereochemical control-are critically summarized. Current limitations and emerging opportunities, such as AI-assisted design, virtual screening, and dynamic combinatorial chemistry, are also discussed. By positioning MCRs as design-enabling technologies, this review outlines a practical framework for the development of next-generation PTP inhibitors.

Indexed as

Covalent and allosteric inhibitionDrug discoveryMulticomponent reactions (MCRs)Protein tyrosine phosphatases (PTPs)PTP inhibitors

Identifiers

PMID42423920

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.